直接口服抗凝药使用者出血与血栓栓塞事件的药物遗传学研究
本研究基于芬兰三个生物库的基因数据与全国登记数据,回顾性分析了1806例达比加群、阿哌沙班或利伐沙班使用者的ABCG2、ABCB1、CES1和CYP3A5基因变异与临床结局的关联。结果显示,ABCB1变异与利伐沙班使用者的血栓栓塞事件风险及阿哌沙班使用者的出血事件风险相关,但需更大样本研究验证。
要点
- ABCB1 c.3435C>T变异与血栓栓塞风险降低相关(HR 0.42)。
- ABCB1单倍型1236C-2677G-3435C和1236T-2677G-3435C与利伐沙班使用者血栓栓塞风险增加相关。
- ABCB1 c.2482-2236G>A变异与阿哌沙班使用者出血风险降低相关(HR 0.37)。
核心结论
- ABCB1基因变异可能是影响利伐沙班使用者血栓栓塞事件和阿哌沙班使用者出血事件的潜在因素。
- 需要更大样本的研究来全面评估DOAC的药物遗传学关联及其临床相关性。
研究设计与样本
- 回顾性真实世界研究,链接芬兰三个生物库的基因型数据与全国药物配发和医疗接触登记数据。
- 共纳入1806例使用阿哌沙班、达比加群或利伐沙班的患者。
- 使用Cox回归模型比较单核苷酸变异或单倍型携带者与非携带者的临床结局发生率。
主要发现
- 在利伐沙班使用者中,ABCB1 c.3435C>T变异与血栓栓塞风险降低相关(HR 0.42,95%CI 0.18-0.98,P=0.044)。
- 在利伐沙班使用者中,单倍型1236T-2677T-3435T与血栓栓塞风险降低相关(HR 0.44,95%CI 0.20-0.95,P=0.036)。
- 在利伐沙班使用者中,单倍型1236C-2677G-3435C与血栓栓塞风险增加相关(HR 2.55,95%CI 1.03-6.36,P=0.044)。
- 在利伐沙班使用者中,单倍型1236T-2677G-3435C与血栓栓塞风险增加相关(HR 5.88,95%CI 2.35-14.72,P<0.001)。
- 在阿哌沙班使用者中,ABCB1 c.2482-2236G>A变异与出血事件风险降低相关(HR 0.37,95%CI 0.16-0.89,P=0.025)。
临床怎么用
- 对于使用利伐沙班或阿哌沙班的患者,ABCB1基因变异可能有助于评估血栓栓塞或出血风险,但当前证据尚不足以指导临床决策。
局限性
- 需要更大样本的研究来全面评估DOAC的药物遗传学关联及其临床相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to analyze associations between genetic variants and the occurrence of clinical outcomes in dabigatran, apixaban, and rivaroxaban users. This was a retrospective real-world study linking genotype data of three Finnish biobanks with national register data on drug dispensations and healthcare encounters. We investigated several single-nucleotide variants (SNVs) in the ABCG2, ABCB1, CES1, and CYP3A5 genes potentially associated with bleeding or thromboembolic events in direct oral anticoagulant (DOAC) users based on earlier research. We used Cox regression models to compare the incidence of clinical outcomes between carriers and noncarriers of the SNVs or haplotypes. In total, 1,806 patients on apixaban, dabigatran, or rivaroxaban were studied. The ABCB1 c.3435C>T (p.Ile1145=, rs1045642) SNV (hazard ratio (HR) 0.42, 95% confidence interval (CI), 0.18-0.98, P = 0.044) and 1236T-2677T-3435T (rs1128503-rs2032582-rs1045642) haplotype (HR 0.44, 95% CI, 0.20-0.95, P = 0.036) were associated with a reduced risk for thromboembolic outcomes, and the 1236C-2677G-3435C (HR 2.55, 95% CI, 1.03-6.36, P = 0.044) and 1236T-2677G-3435C (HR 5.88, 95% CI, 2.35-14.72, P < 0.001) haplotypes with an increased risk for thromboembolic outcomes in rivaroxaban users. The ABCB1 c.2482-2236G>A (rs4148738) SNV associated with a lower risk for bleeding events (HR 0.37, 95% CI, 0.16-0.89, P = 0.025) in apixaban users. ABCB1 variants are potential factors affecting thromboembolic events in rivaroxaban users and bleeding events in apixaban users. Studies with larger numbers of patients are warranted for comprehensive assessment of the pharmacogenetic associations of DOACs and their relevance for clinical practice.
引用
- Lähteenmäki J, Vuorinen AL, Pajula J, et al. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. Clin Pharmacol Ther. 2021. PMID: 34043814. doi:10.1002/cpt.2316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。